292 related articles for article (PubMed ID: 30478799)
21. Cerebrospinal fluid HIV escape associated with progressive neurologic dysfunction in patients on antiretroviral therapy with well controlled plasma viral load.
Peluso MJ; Ferretti F; Peterson J; Lee E; Fuchs D; Boschini A; Gisslén M; Angoff N; Price RW; Cinque P; Spudich S
AIDS; 2012 Sep; 26(14):1765-74. PubMed ID: 22614889
[TBL] [Abstract][Full Text] [Related]
22. Soluble TLR2 and 4 concentrations in cerebrospinal fluid in HIV/SIV-related neuropathological conditions.
Mothapo KM; Ten Oever J; Koopmans P; Stelma FF; Burm S; Bajramovic J; Verbeek MM; Rikkert MGO; Netea MG; Koopman G; van der Ven AJ
J Neurovirol; 2017 Apr; 23(2):250-259. PubMed ID: 27882497
[TBL] [Abstract][Full Text] [Related]
23. Elevated plasma soluble CD14 and skewed CD16+ monocyte distribution persist despite normalisation of soluble CD163 and CXCL10 by effective HIV therapy: a changing paradigm for routine HIV laboratory monitoring?
Castley A; Berry C; French M; Fernandez S; Krueger R; Nolan D
PLoS One; 2014; 9(12):e115226. PubMed ID: 25544986
[TBL] [Abstract][Full Text] [Related]
24. Low levels of HIV-1 RNA detected in the cerebrospinal fluid after up to 10 years of suppressive therapy are associated with local immune activation.
Dahl V; Peterson J; Fuchs D; Gisslen M; Palmer S; Price RW
AIDS; 2014 Sep; 28(15):2251-8. PubMed ID: 25022595
[TBL] [Abstract][Full Text] [Related]
25. Treatment intensification has no effect on the HIV-1 central nervous system infection in patients on suppressive antiretroviral therapy.
Yilmaz A; Verhofstede C; D'Avolio A; Watson V; Hagberg L; Fuchs D; Svennerholm B; Gisslén M
J Acquir Immune Defic Syndr; 2010 Dec; 55(5):590-6. PubMed ID: 20847699
[TBL] [Abstract][Full Text] [Related]
26. Increased blood-brain barrier permeability in neuro-asymptomatic HIV-1-infected individuals--correlation with cerebrospinal fluid HIV-1 RNA and neopterin levels.
Andersson LM; Hagberg L; Fuchs D; Svennerholm B; Gisslén M
J Neurovirol; 2001 Dec; 7(6):542-7. PubMed ID: 11704886
[TBL] [Abstract][Full Text] [Related]
27. Soluble CD14 in cerebrospinal fluid is associated with markers of inflammation and axonal damage in untreated HIV-infected patients: a retrospective cross-sectional study.
Jespersen S; Pedersen KK; Anesten B; Zetterberg H; Fuchs D; Gisslén M; Hagberg L; Trøseid M; Nielsen SD
BMC Infect Dis; 2016 Apr; 16():176. PubMed ID: 27103116
[TBL] [Abstract][Full Text] [Related]
28. Cerebrospinal fluid extracellular vesicles and neurofilament light protein as biomarkers of central nervous system injury in HIV-infected patients on antiretroviral therapy.
Guha D; Mukerji SS; Chettimada S; Misra V; Lorenz DR; Morgello S; Gabuzda D
AIDS; 2019 Mar; 33(4):615-625. PubMed ID: 30557159
[TBL] [Abstract][Full Text] [Related]
29. Cerebrospinal fluid viral load in HIV-1-infected patients without antiretroviral treatment: a longitudinal study.
Gisslén M; Hagberg L; Fuchs D; Norkrans G; Svennerholm B
J Acquir Immune Defic Syndr Hum Retrovirol; 1998 Apr; 17(4):291-5. PubMed ID: 9525428
[TBL] [Abstract][Full Text] [Related]
30. Immune activation of the central nervous system is still present after >4 years of effective highly active antiretroviral therapy.
Edén A; Price RW; Spudich S; Fuchs D; Hagberg L; Gisslén M
J Infect Dis; 2007 Dec; 196(12):1779-83. PubMed ID: 18190258
[TBL] [Abstract][Full Text] [Related]
31. Prevalence and Correlates of Persistent HIV-1 RNA in Cerebrospinal Fluid During Antiretroviral Therapy.
Anderson AM; Muñoz-Moreno JA; McClernon DR; Ellis RJ; Cookson D; Clifford DB; Collier AC; Gelman BB; Marra CM; McArthur JC; McCutchan JA; Morgello S; Sacktor N; Simpson DM; Franklin DR; Heaton RK; Grant I; Letendre SL;
J Infect Dis; 2017 Jan; 215(1):105-113. PubMed ID: 27789723
[TBL] [Abstract][Full Text] [Related]
32. Central nervous system immune activation characterizes primary human immunodeficiency virus 1 infection even in participants with minimal cerebrospinal fluid viral burden.
Spudich S; Gisslen M; Hagberg L; Lee E; Liegler T; Brew B; Fuchs D; Tambussi G; Cinque P; Hecht FM; Price RW
J Infect Dis; 2011 Sep; 204(5):753-60. PubMed ID: 21844301
[TBL] [Abstract][Full Text] [Related]
33. Galectin-9 is rapidly released during acute HIV-1 infection and remains sustained at high levels despite viral suppression even in elite controllers.
Tandon R; Chew GM; Byron MM; Borrow P; Niki T; Hirashima M; Barbour JD; Norris PJ; Lanteri MC; Martin JN; Deeks SG; Ndhlovu LC
AIDS Res Hum Retroviruses; 2014 Jul; 30(7):654-64. PubMed ID: 24786365
[TBL] [Abstract][Full Text] [Related]
34. No support for premature central nervous system aging in HIV-1 when measured by cerebrospinal fluid phosphorylated tau (p-tau).
Krut JJ; Price RW; Zetterberg H; Fuchs D; Hagberg L; Yilmaz A; Cinque P; Nilsson S; Gisslén M
Virulence; 2017 Jul; 8(5):599-604. PubMed ID: 27435879
[TBL] [Abstract][Full Text] [Related]
35. CSF inflammatory markers and neurocognitive function after addition of maraviroc to monotherapy darunavir/ritonavir in stable HIV patients: the CINAMMON study.
Barber TJ; Imaz A; Boffito M; Niubó J; Pozniak A; Fortuny R; Alonso J; Davies N; Mandalia S; Podzamczer D; Gazzard B
J Neurovirol; 2018 Feb; 24(1):98-105. PubMed ID: 29280108
[TBL] [Abstract][Full Text] [Related]
36. Biomarkers of chemotaxis and inflammation in cerebrospinal fluid and serum in individuals with HIV-1 subtype C versus B.
de Almeida SM; Rotta I; Jiang Y; Li X; Raboni SM; Ribeiro CE; Smith D; Potter M; Vaida F; Letendre S; Ellis RJ;
J Neurovirol; 2016 Dec; 22(6):715-724. PubMed ID: 27400932
[TBL] [Abstract][Full Text] [Related]
37. Elevated Cerebrospinal Fluid Anti-CD4 Autoantibody Levels in HIV Associate with Neuroinflammation.
Cheng D; Luo Z; Fu X; Stephenson S; Di Germanio C; Norris PJ; Fuchs D; Ndhlovu LC; Li QZ; Zetterberg H; Gisslen M; Price RW; Peng S; Jiang W
Microbiol Spectr; 2022 Feb; 10(1):e0197521. PubMed ID: 34985329
[TBL] [Abstract][Full Text] [Related]
38. Cerebrospinal fluid HIV RNA and drug levels with combination ritonavir and saquinavir.
Kravcik S; Gallicano K; Roth V; Cassol S; Hawley-Foss N; Badley A; Cameron DW
J Acquir Immune Defic Syndr; 1999 Aug; 21(5):371-5. PubMed ID: 10458617
[TBL] [Abstract][Full Text] [Related]
39. Changes in CSF and plasma HIV-1 RNA and cognition after starting potent antiretroviral therapy.
Marra CM; Lockhart D; Zunt JR; Perrin M; Coombs RW; Collier AC
Neurology; 2003 Apr; 60(8):1388-90. PubMed ID: 12707454
[TBL] [Abstract][Full Text] [Related]
40. Cerebrospinal fluid viral load, intrathecal immunoactivation, and cerebrospinal fluid monocytic cell count in HIV-1 infection.
Gisslén M; Fuchs D; Svennerholm B; Hagberg L
J Acquir Immune Defic Syndr; 1999 Aug; 21(4):271-6. PubMed ID: 10428104
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
